Use of Intravenous Gadolinium-Based Contrast Media in Patients With Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation
| Autor: | Matthew S. Davenport, Jeffrey C. Weinreb, Derek M. Fine, Jerry Yee, Roger A. Rodby, Jonathan R. Dillman, Carolyn L. Wang, Robert J. McDonald, Mark A. Perazella |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Consensus Gadolinium Group ii Contrast Media chemistry.chemical_element Renal function Kidney Internal Medicine medicine Humans Radiology Nuclear Medicine and imaging In patient Special Report Societies Medical business.industry medicine.disease United States medicine.anatomical_structure chemistry Nephrology Nephrogenic systemic fibrosis Administration Intravenous Kidney Diseases Radiology business Kidney disease |
| Zdroj: | Kidney Medicine |
| ISSN: | 2590-0595 |
| Popis: | Inaugural consensus statements were developed and endorsed by the American College of Radiology (ACR) and National Kidney Foundation to improve and standardize the care of patients with kidney disease who have indication(s) to receive ACR-designated group II or group III intravenous gadolinium-based contrast media (GBCM). The risk of nephrogenic systemic fibrosis (NSF) from group II GBCM in patients with advanced kidney disease is thought to be very low (zero events following 4931 administrations to patients with estimated glomerular filtration rate [eGFR] |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|